



Preferred Clinic Location

- ☐ **Harbor Health Park Bend Clinic**
2200 Park Bend Drive, Bldg 2, Suite 300, Austin, TX 78758
P: (855) 481-8375
F: (512) 233-2288

Patient Information

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

Date: _____ Patient Name: _____ DOB: _____
ICD-10 code (required): _____ ICD-10 description: _____
☐ NKDA Allergies: _____ Weight (lbs/kg): _____ Height: _____
Patient Status: ☐ New to Therapy ☐ Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

Provider Information

Referral Coordinator Name: _____ Referral Coordinator Email: _____
Ordering Provider: _____ Provider NPI: _____
Referring Practice Name: _____ Phone: _____ Fax: _____
Practice Address: _____ City: _____ State: _____ Zip Code: _____

Supporting Documents/Information (Please provide all of the following)

- Patient insurance information
- Patient medication list
- Clinicals to support one or more of the following:
 - Adult patients with moderately to severely active ulcerative colitis
 - Recent TB test results

Orders

NURSING

- ☒ Nursing care per [Harbor Health Nursing Procedures](#) and [Harbor Health Adverse Reaction Management Protocol](#).

LABORATORY

- ☐ CBC ☐ at each dose ☐ every _____
☐ CMP ☐ at each dose ☐ every _____
☐ CRP ☐ at each dose ☐ every _____
☐ Other: _____

PRE-MEDICATION

(Administer 30 minutes prior to procedure)

- ☐ acetaminophen (Tylenol) ☐ 500mg / ☐ 650mg / ☐ 1000mg PO
☐ cetirizine (Zyrtec) 10mg PO
☐ loratadine (Claritin) 10mg PO
☐ diphenhydramine (Benadryl) ☐ 25mg / ☐ 50mg ☐ PO / ☐ IV
☐ methylprednisolone (Solu-Medrol) ☐ 40mg / ☐ 125mg IV
☐ hydrocortisone (Solu-Cortef) ☐ 100mg IV
☐ Other: _____
Dose: _____ Route: _____ Frequency: _____

THERAPY INDUCTION

- ☐ **Guselkumab** (Tremfya) induction IV dose
- Dose: 200 mg in 250ml 0.9% sodium chloride
 - Frequency: week 0, week 4, and week 8
 - Route: ☒ Infuse intravenously over 1 hour
- ☐ Flush with 0.9% sodium chloride at infusion completion
- ☐ After the 8 week induction dose, maintenance will continue with subcutaneous injections if appropriate. Subsequent orders for subcutaneous continuation are below.

THERAPY MAINTENANCE

- ☐ 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter
- ☐ 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter
- ☐ Other _____mg at Week _____ and every _____ weeks thereafter

Use the lowest effective recommended dosage to maintain therapeutic response.

Provider Name (Print): _____

Provider Signature: _____

Date: _____